

Agenda

Discuss Pilot Project

1. Potential study designs, Current designs [Nick Petrick]
2. Phantom Selection [Chuck Fenimore]

Did not get to these items, should discuss on next weeks call

3. Volume computation methods [Rick Avila]
4. Endpoints/statistical assessment for pilot project

Discuss benefits of quantitative CT

1. Drug development (early?) [David Mozley]
2. Clinical oncology [Jim Mulshine]

Strategize relationships with other groups (Agenda item from last week)

Notes from June 16 2008 WebEx

- Showed FDA phantom study data from [Nick Petrick]
 - Interesting to run this phantom through PET/CT systems
 - Would be of interest to compare a number of different software tools with the phantom data
 - FDA not planning to extend into different clinical areas
 - Need to get feedback from clinical groups and pharma on would be required for “good enough” quantitation for CT imaging in each different setting
 - Once patient has known cancer, may be better to use dose necessary to get appropriate clinical question answered.
 - All of this FDA imaging data will be available to the public at some point in time.
 - o First large scale release will be in Fall 2008 for general public.

NIST very interested in the evaluation of the software out in use.

- Chuck is discussing with those within NIST on objects imbedded within gels and other potential phantoms.

Need to look at both phantoms with known true volume and clinical cases when we don't know the actual volume

- Critical to look at both of these to identify different sources of variability, both hardware and reader effects.

Action items

1. To what extent will the spherical data to be available in the Fall meet the needs of this group and what we might want to add as additional experiments (For group discussion)